Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 38.1% during trading on Thursday . The company traded as high as C$0.15 and last traded at C$0.15. 605,625 shares were traded during trading, an increase of 51% from the average session volume of 401,760 shares. The stock had previously closed at C$0.11.
Hemostemix Stock Performance
The firm has a market capitalization of C$12.63 million, a P/E ratio of -7.25 and a beta of 0.20. The stock has a 50 day moving average of C$0.09 and a two-hundred day moving average of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- The Risks of Owning Bonds
- Warren Buffett Bets on the Digital Economy With New VeriSign Buy
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Discover 2 Under-the-Radar Aerospace Stocks Set for 2025 Growth
- 3 Warren Buffett Stocks to Buy Now
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
